Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV;<i>Boostrix™</i>IPV)

Knuf, Markus; Vetter, Volker; Celzo, Froilan; Ramakrishnan, Gunasekaran; Meeren, Olivier Van Der; Jacquet, Jeanne Marie

doi:10.4161/hv.6.7.11760

Cited by 22 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerning diphtheria, before the booster dose in adolescence, 89.2% and 85.5% of subjects were seroprotected by ELISA, respectively, having previously received dTap-IPV or dTap. By using the neutralization test, the seroprotection rate was equal to 98.2% and 95.2%, respectively, in those who had previously received dTap-IPV or dTap [41]. In 2011, Scott has published a review on the results obtained with a dTap vaccine containing 5 pertussis components.…”

Section: Resultsmentioning

confidence: 99%

Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster

Gabutti

Trucchi

Conversano³

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

The need for boosters for tetanus, diphtheria, pertussis, and polio, starting from preschool age, is related to the waning immune protection conferred by vaccination, the elimination/reduction of natural boosters due to large-scale immunization programs, and the possibility of reintroduction of wild agents from endemic areas. Taking into account the relevance of safety/tolerability in the compliance with vaccination among the population, it have been assessed whether today enough scientific evidences are available to support the use of dTap-IPV booster in preschool age. The review of the literature was conducted using the PubMed search engine. A total of 41 works has been selected; besides, the documentation produced by the World Health Organization, the European Centre for Disease Control, and the Italian Ministry of Health has been consulted. Many recent papers confirm the opportunity to use a low antigenic dose vaccine starting from 4 to 6 years of age. There is also evidence that 10 years after immunization the rate of seroprotected subjects against diphtheria does not differ significantly between those vaccinated with paediatric dose (DTaP) or reduced dose (dTaP or dTap) product. The dTpa vaccine is highly immunogenic for diphtheria toxoids regardless of prior vaccination history (2 + 1 and 3 + 1 schedules).

show abstract

Section: Resultsmentioning

confidence: 99%

Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster

Gabutti

Trucchi

Conversano³

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…However, there is unlikely to be any immediately relevant clinical impact of this observation as antibody levels against diphtheria were well above the correlate of seroprotection of 0.1 IU/ml. Anti-diphtheria seroprotection rates induced by the low-strength dTpa-IPV vaccine persisted up to 10 y post-dTpa booster in long-term follow-up studies involving children, adolescents and adults 16 , 18 , 19 …”

Section: Discussionmentioning

confidence: 97%

“…A study performed in adolescents in Germany (primed with reduced antigen dTpa-IPV vaccines as pre-school children) demonstrated consistent (98.2%) protection against diphtheria at the pre-adolescent booster timepoint and 100% seroprotection after the booster dose in adolescence 16 . Pertussis antibody titers measured after vaccination with the reduced antigen dTpa-IPV vaccine were higher than those observed in household contact efficacy trials of pertussis prevention 16 , 22 …”

Section: Discussionmentioning

confidence: 98%

“…However, a mathematical model has predicted that following reduced-antigen-content dTpa vaccines, protective levels of anti-diphtheria antibodies comparable to full-strength DTPa can be maintained for 10 y 14 . This is further substantiated by data from long-term follow up studies where persistence of immunity was measured up to 10 y after dTpa booster dose 16 , 18 , 19 …”

Section: Introductionmentioning

confidence: 97%

“…Furthermore, the dTpa vaccine induces high immunogenicity to all antigens, 16 although a previous study in Italy reported that post-booster anti-diphtheria geometric mean concentrations (GMCs) were significantly lower after the reduced-antigen-content dT vaccine compared with the full-strength DT vaccine 17 . Since post-vaccination anti-diphtheria titers relate to duration of immunity, it was assumed at that time that reduced-antigen-content dT vaccines would offer less prolonged protection when compared with full-strength DT vaccines 14 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine

Ferrera

Cuccia²,

Mereu³

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background: Pertussis occurs in older children, adolescents and adults due to waning immunity after primary vaccination. Booster vaccination for pre-school children has been recommended in Italy since 1999. In this study (NCT00871000), the immunogenicity, safety and reactogenicity of a booster dose of reduced-antigen content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (dTpa-IPV; GSK Biologicals Boostrix™-Polio; 3-component pertussis) vs. full-strength DTPa-IPV vaccine (sanofi-pasteur—MSD Tetravac™; 2-component pertussis) was evaluated in pre-school Italian children. Methods: Healthy children aged 5–6 y primed in a routine vaccination setting with three doses of DTPa-based vaccines were enrolled and randomized (1:1) in this phase IIIb, booster study to receive a single dose of dTpa-IPV or DTPa-IPV; the MMRV vaccine was co-administered. Antibody concentrations/titers against diphtheria, tetanus, pertussis and poliovirus 1–3 were measured before and one month post-booster. Reactogenicity and safety was assessed.Results: 305 subjects were enrolled of whom 303 (dTpa-IPV = 151; DTPa-IPV = 152) received booster vaccination. One month post-booster, all subjects were seroprotected/seropositive for anti-diphtheria, anti-tetanus, anti-PT, anti-FHA and anti-poliovirus 1–3; 99.3% of dTpa-IPV and 60.4% of DTPa-IPV subjects were seropositive for anti-PRN; 98–100% of subjects were seropositive against MMRV antigens post-booster. Pain at the injection site (dTpa-IPV: 63.6%; DTPa-IPV: 63.2%) and fatigue (dTpa-IPV: 26.5%; DTPa-IPV: 23.7%) were the most commonly reported solicited local and general symptoms, during the 4-d follow-up period. No SAEs or fatalities were reported.Conclusions: The reduced-antigen-content dTpa-IPV vaccine was non-inferior to full-strength DTPa-IPV vaccine with respect to immunogenicity. The vaccine was well-tolerated and can be confidently used as a booster dose in pre-school children.

show abstract

Poliovirus Vaccine–Inactivated

Plotkin¹,

Vidor²

2018

Plotkin's Vaccines

View full text Add to dashboard Cite

Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV;Boostrix™IPV)

Cited by 22 publications

References 23 publications

Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster

Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster

Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine

Poliovirus Vaccine–Inactivated

Contact Info

Product

Resources

About